Structure Therapeutics (GPCR) Payables (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Payables of $7.8 million for Q1 2026, down 10.2% year-over-year from $8.7 million in Q1 2025, and down 43.58% quarter-over-quarter from $13.9 million in Q4 2025.
Structure Therapeutics (GPCR) Payables (2022 - 2026) Analysis & Trends
Structure Therapeutics' Payables history runs 5 years deep, the most recent figure standing at $7.8 million for Q1 2026.
- In Q1 2026, Payables fell 10.2% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $7.8 million (down 10.2% YoY), while the FY2025 annual figure was $13.9 million, up 72.78% from the prior year.
- Payables for Q1 2026 stood at $7.8 million, down from $13.9 million in the prior quarter.
- The five-year high for Payables was $17.8 million in Q3 2025, with the low at $2.2 million in Q2 2024.
- The 5-year median for Payables is $7.2 million (2024), against an average of $7.7 million.
- The sharpest annual moves came in 2024 and 2025: Payables tumbled 61.24% in 2024, then soared 306.97% in 2025.
- Structure Therapeutics' Payables stood at $6.0 million in 2022, then retreated by 21.09% to $4.7 million in 2023, then soared by 69.21% to $8.0 million in 2024, then surged by 72.78% to $13.9 million in 2025, then sank by 43.58% to $7.8 million in 2026.
- Business Quant data shows GPCR's Payables at $7.8 million in Q1 2026, $13.9 million in Q4 2025, and $17.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 11.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.13 Mn |
| Mar 31, 2026 | 7.82 Mn |
| Dec 31, 2025 | 13.86 Mn |
| Sep 30, 2025 | 17.80 Mn |
| Jun 30, 2025 | 8.99 Mn |
| Mar 31, 2025 | 8.71 Mn |
| Dec 31, 2024 | 8.02 Mn |
| Sep 30, 2024 | 8.45 Mn |
| Jun 30, 2024 | 2.21 Mn |
| Mar 31, 2024 | 6.54 Mn |
| Dec 31, 2023 | 4.74 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | 5.70 Mn |
| Mar 31, 2023 | 4.95 Mn |
| Dec 31, 2022 | 6.01 Mn |